NZ763815B2 - Methods of using and compositions containing dulaglutide - Google Patents
Methods of using and compositions containing dulaglutide Download PDFInfo
- Publication number
- NZ763815B2 NZ763815B2 NZ763815A NZ76381518A NZ763815B2 NZ 763815 B2 NZ763815 B2 NZ 763815B2 NZ 763815 A NZ763815 A NZ 763815A NZ 76381518 A NZ76381518 A NZ 76381518A NZ 763815 B2 NZ763815 B2 NZ 763815B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- dulaglutide
- dose
- once weekly
- methods
- compositions containing
- Prior art date
Links
- 229960005175 dulaglutide Drugs 0.000 title claims abstract 10
- 108010005794 dulaglutide Proteins 0.000 title claims abstract 10
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003442 weekly effect Effects 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000013585 weight reducing agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The present invention relates to methods of using new doses of dulaglutide and compositions containing such higher doses of dulaglutide given in a dosage regime with increasing dosages from 0.75 mg weekly up to 4.5 mg weekly resulting in less side effects.
Claims (4)
1. Use of dulaglutide in the manufacture of a medicament for improving glycemic control in a subject in need thereof with type 2 diabetes, wherein: a) said medicament is to be administered to said subject in an initial dose of 5 0.75 mg of dulaglutide once weekly; b) said dose is to be increased to 1.5 mg of dulaglutide once weekly c) said dose is to be increased to 3.0 mg of dulaglutide once weekly after at least 4 weeks on the 1.5 mg dose; and d) said dose is to be increased to 4.5 mg of dulaglutide once weekly after at 10 least 4 weeks on the 3.0 mg dose.
2. The use of claim 1, wherein the dose increases of each of steps b) through d) are performed when there is a need to reduce the subject’s HbA1c level.
3. The use of claim 2, wherein administration of 4.5 mg of dulaglutide once weekly results in a greater body weight reduction than administration of 1.5 mg of 15 dulaglutide once weekly.
4. Use of any one of claims 1 to 3 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ763815A NZ763815A (en) | 2023-11-24 |
| NZ763815B2 true NZ763815B2 (en) | 2024-02-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2867343C (en) | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| CA2653201A1 (en) | Compositions and uses of e3-gp19k for treating diabetes | |
| RU2017134443A (en) | METHOD OF TREATMENT WITH USE OF TRADIPTANT | |
| JP2016512564A5 (en) | ||
| IT8922725A1 (en) | USE OF IMMUNOMODULANTS AS SYNERGIC AGENTS OF CHEMOTHERAPY IN CANCER THERAPY | |
| FI3229828T3 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| Harbeck et al. | Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH) | |
| Drüeke et al. | Oral or intravenous iron for anemia correction in chronic kidney disease? | |
| JP2021004249A5 (en) | ||
| JP2016512247A5 (en) | ||
| MX2021009219A (en) | Triamterene or nolatrexed for use in the treatment of phenylketonuria. | |
| NZ763815B2 (en) | Methods of using and compositions containing dulaglutide | |
| NZ763815A (en) | Methods of using and compositions containing dulaglutide | |
| Mao | Thymosin alpha 1–Reimagine its broader applications in the immuno-oncology era | |
| Oshima et al. | Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT | |
| MX2023004832A (en) | Method of safe administration of anti-tau antibody. | |
| RU2017129068A (en) | METHOD OF TREATMENT OR PREVENTION OF ATHEROTROMBOTIC PHENOMENA IN PATIENTS WITH MYOCARDIAL INFARCTION IN ANAMSES | |
| JP2005508323A5 (en) | ||
| MX2022001153A (en) | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab. | |
| Moore et al. | Response of murine jejunal crypts to single doses of cyclophosphamide and radiation | |
| CO2020000529A2 (en) | Methods to treat congenital hyperinsulinism | |
| JP2021502379A5 (en) | ||
| Koschmieder et al. | Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN) | |
| Puig | Treatment of severe psoriasis | |
| Bethel et al. | Impact of sitagliptin on cardiovascular and safety-related outcomes in insulin-treated type 2 diabetes: the TECOS experience |